Clinical development of antivirals against SARS-CoV-2 and its variants
The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although many newly developed antivirals and repurposed antivirals have been applied to the treatment of coronavirus disease 2019 (COVID-19), antivirals showin...
Main Authors: | Qiaoshuai Lan, Yan Yan, Guangxu Zhang, Shuai Xia, Jie Zhou, Lu Lu, Shibo Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | Current Research in Microbial Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666517423000299 |
Similar Items
-
Host antiviral factors hijack furin to block SARS-CoV-2, ebola virus, and HIV-1 glycoproteins cleavage
by: Changqing Yu, et al.
Published: (2023-12-01) -
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
by: Varghese Edwin Hillary, et al.
Published: (2023-03-01) -
Development of SARS-CoV-2 entry antivirals
by: Meiyue Dong, et al.
Published: (2024-02-01) -
Nanostructures for prevention, diagnosis, and treatment of viral respiratory infections: from influenza virus to SARS-CoV-2 variants
by: Esmaeel Sharifi, et al.
Published: (2023-06-01) -
Antiviral Effect of Budesonide against SARS-CoV-2
by: Natalie Heinen, et al.
Published: (2021-07-01)